1 / 8

NE CENTER FOR NEUROLOGICAL DISORDERS

NE CENTER FOR NEUROLOGICAL DISORDERS. Group Members Tsuneya Ikezu - Dept of Pharmacology - UNMC Yutong Liu -Dept of Radiology - UNMC Li Tan - Engineering Mechanics - UNL Luwen Zhang - Virology Center - UNL David Holtzclaw - Dept of Physiology - UNMC

justis
Download Presentation

NE CENTER FOR NEUROLOGICAL DISORDERS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NE CENTER FOR NEUROLOGICAL DISORDERS • Group Members • Tsuneya Ikezu - Dept of Pharmacology - UNMC • Yutong Liu -Dept of Radiology - UNMC • Li Tan - Engineering Mechanics - UNL • Luwen Zhang - Virology Center - UNL • David Holtzclaw - Dept of Physiology - UNMC • Yazen Alnouti - Dept. of Pharmaceutical Sci - UNMC • Ron Cerny - Dept. of Chemistry - UNL • David Berkowitz - Dept of Chemistry - UNL

  2. Charge: • Your task is to develop core ideas/projects for an $8-10M ($1.25-1.5M per year for 5 years) NIH Center proposal. • Specifically, you should consider the following questions

  3. Briefly describe the core projects your group would design for the Center. Please dream big. • Alz-Novel Druggable Target 1:Identification of the first inhibitors for Tao-Tubulin Kinases (TTBK) I and II (I-Alzheimers, II-Spinocerebellar ataxia) -Ikezu • Alz-Novel Druggable Target 2:Identification of the first inhibitors for Serine Racemase (hSR) (Alzheimers, stroke)-Berkowitz • CNS-Lymphoma: Interferon Regulatory Factor-4 (IRF4) as novel transcription factor/emerging lymphoma target-Zhang • Novel Approaches to Neuro-Imaging Use of Mn-, Gd- and Fe-based paramagnetic contrast agents for neuro-MRI (50 uM resolution/stroke model) -Liu, fluorescence with novel self-assembled agents- Tan • Drug Metabolism/Optimization Cyt-P450-based drug candidate metabolism - hot spot/byproduct identification by LC/MS-Alouti, Cerny

  4. Identify the key faculty from from both campuses to involve in these projects. Include their strengths. (UNMC on next slide) • UNL FacultyStrengths David Berkowitz Enzyme Inhibitor Development Li Tan Novel Fluorescent Materials Ron Cerny NE Proteomics Center Director Luwen Zhang NE Virology - Lymophoma Pat Dussault Medicinal/Natural Prod Chem James Takacs Medicinal/Natural Prod Chem

  5. Identify the key faculty from from both campuses to involve in these projects. Include their strengths. • UNMC Faculty Strengths Tsuneya Ikezu Neurodegen Disorders Howard Gendelman Nanomedicine Yazen Alnouti Drug Metab/Pharmacokinetics Yutong Liu Radiology/MRI David Holtzclaw Fluid Mechanics Hong Sun Rat Stroke Model (Physiol)

  6. Identify external academic partners & expertise or equipment resources/strengths that are needed to accomplish these projects. Harvard Neurodegenerative Disorder Program (High throughput drug screening) UNMC MRI Center ( Liu) NE Center for Proteomics (Cerny) KU cpd library & HTS facility (Scott Wier)

  7. List potential industry/foundation partners (think broadly) and what they would contribute. Include reasons why they would be interested. Neumedix - Australia/Cayman Islands (VC interest in TTBK inhibition with Prof. Ikezu) Merck, Wyeth-Pfizer, Astrazeneca, GSK, BMS (Drug development for Alzheimers, stroke and CNS-lymphoma)

  8. Describe how you would link the Center to other campus resources.

More Related